CRISPR-based gene therapy approved in Europe for two blood disorders

Casgevy, a CRISPR-based gene therapy, was one of the first cell-based gene therapies granted approval by the the Medicines and Healthcare products Regulatory Agency in the UK for the treatment of sickle cell disease and transfusion-dependent beta-thalassemia in patients 12 years and older (see BioNews 1216)

Approval in the USA by the Food and Drug Administration followed (see BioNews 1220 and 1223).

Now, the European Commission has approved the drug for treatment of the conditions in the European Union, as reported by Forbes.